Nicholas J. Short, MD, on ALL: Ponatinib Plus Blinatumomab May Help Patients Avoid Transplants

June 15, 2021 By The ASCO Post Staff

Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses early results from a phase II study which showed that combining ponatinib and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia may prove to be an effective chemotherapy-free regimen that might reduce the need for allogeneic hematopoietic stem cell transplant (Abstract 7001).

Related Content